Schistosomiasis

Jump to navigation Jump to search
Schistosomiasis
Skin vesicles created by the penetration of Schistosoma. Source: CDC
ICD-10 B65
ICD-9 120
MeSH D012552

Schistosomiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Schistosomiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Schistosomiasis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Schistosomiasis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Schistosomiasis

CDC on Schistosomiasis

Schistosomiasis in the news

Blogs on Schistosomiasis

Directions to Hospitals Treating Schistosomiasis

Risk calculators and risk factors for Schistosomiasis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]




Treatment

Schistosomiasis is readily treated using a single oral dose of the drug Praziquantel. While Praziquantel is safe and highly effective in curing an infected patient, it does not prevent re-infection by cercariae and is thus not an optimum treatment for people living in endemic areas. As with other major parasitic diseases, there is ongoing and extensive research into developing a vaccine that will prevent the parasite from completing its life cycle in humans.

Antimony has been used in the past to treat the disease. In low doses, this toxic metalloid bonds to sulfur atoms in enzymes used by the parasite and kills it without harming the host. This treatment is not referred to in present-day peer-review scholarship; Praziquantel is universally used. Outside of the US, there is a second drug available for treating Schistosoma mansoni (exclusively) called Oxamniquine.

Mirazid, a new Egyptian drug, is under investigation for oral treatment of the disease.

Experiments have shown medicinal Castor oil as an oral anti-penetration agent to prevent Schistosomiasis and that praziquantel's effectiveness depended upon the vehicle used to administer the drug (e.g., Cremophor / Castor oil).[1]

Additionally Dr Chidzere of Zimbabwe researched the Gopo Berry (Phytolacca dodecandra) during the 1980's and found that the Gopo Berry could be used in the control of the freshwater snails which carry the bilharzia disease (Schistosomiasis parasite). Dr Chidzere in his interview to Andrew Blake (1989) reported concerns of muti-national chemical companies keen to rubbish the Gopu Berry alternative for snail control [2]. Reputedly Gopo Berries from hotter Ethiopia climates yield the best results. Later studies were between 1993-95 by the Danish Research Network for international health. [3]

Prevention through good design

The main focus of prevention is eliminating the water-borne snails which are natural reservoirs for the disease. This is usually done by identifying bodies of water, such as lakes, ponds, etc., which are infested, forbidding or warning against swimming and adding niclosamide, acrolein, copper sulfate, etc., to the water in order to kill the snails.

Unfortunately for many years from the 1950s onwards, despite the efforts of some clinicians to get civil engineers to take it into account in their designs, civil engineeers built vast dam and irrigation schemes, oblivious of the fact that they would cause a massive rise in water-borne infections from schistosomiasis, even though with a little care the schemes could have been designed to minimise such effects, the detailed specifications having been laid out in various UN documents since the 1950s. Irrigation schemes can be designed to make it hard for the snails to colonise the water, and to reduce the contact with the local population. [4]

Failure for engineers to take this into account is an interesting example of the Relevance Paradox and is a good example of the failure of formal education and information systems to transmit tacit knowledge.

Prevention and hygiene

Prevention is best accomplished by eliminating the water-dwelling snails which are the natural reservoir of the disease. Acrolein, copper sulfate, and niclosamide can be used for this purpose. Recent studies have suggested that snail populations can be controlled by the introduction or augmentation of existing crayfish populations; as with all ecological interventions, however, this technique must be approached with caution.

Individuals can guard against schistosomiasis infection by avoiding bodies of water known or likely to harbor the carrier snails.

In 1989, Aklilu Lemma and Legesse Wolde-Yohannes received the Right Livelihood Award for their research on the sapindus-Plant (Phytolacca dodecandra), as a preventative measure for the disease.

Histopathology: Rectum, Schistosomiasis

{{#ev:youtube|9VpqxnPRvL8}}

See also

References

  1. "Schistosoma mansoni: experimental chemoprophylaxis in mice using oral anti-penetration agents". pubmed. Retrieved 2007-01-25.
  2. The Gopu Berry p33. Part 4 School Journal number.2 1989 Dept of Education Wellington N.Z
  3. http://enrecahealth.ku.dk/postgrad_dbl_en/chihaka_abs/
  4. Charnock, Anne (1980) Taking Bilharziasis out of the irrigation equation. New Civil Engineer, 7 August. 1980 Bilharzia caused by poor civil engineering design due to ignorance of cause and prevention

External links


Template:Link FA Template:Helminthiases


ar:بلهارسيا de:Schistosomiasis eo:Helika febro it:Schistosomiasi lt:Šistosomozė nl:Schistosomiasis fi:Skistosomiaasi sv:Snäckfeber


Template:WikiDoc Sources